XP21279: Completed Phase IIb enrollment

XenoPort disclosed in its 2Q11 earnings that it completed enrollment of about 48 PD patients with motor fluctuations in a double-blind, U.S. Phase IIb trial evaluating XP21279 and carbidopa vs. Sineme...